E. Spanoudakis

Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine

S. Papageorgiou, V. Pappa, I. Kotsianidis, 2013, Blood Cancer Journal.

Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology

N. Giannakoulas, I. Kotsianidis, X. Yataganas, 2006, Annals of Hematology.

Hydroxyurea and Anagrelide Combination Therapy in Patients with Chronic Myeloproliferative Diseases Resistant or Intolerant to Monotherapy

D. Margaritis, I. Kotsianidis, G. Bourikas, 2009, Acta Haematologica.

Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms.

I. Kotsianidis, E. Nakou, P. Miltiades, 2015, Leukemia research.

Proteolytic Matrix Metallopeptidases and Inhibitors in BCR-ABL1-Negative Myeloproliferative Neoplasms: Correlation with JAK2V617F Mutation Status

D. Margaritis, D. Margaritis, I. Kotsianidis, 2011, Acta Haematologica.

Long‐term remission of recalcitrant tumour‐stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin

D. Margaritis, I. Kotsianidis, G. Bourikas, 2003, Journal of the European Academy of Dermatology and Venereology : JEADV.

The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine

A. Scorilas, S. Papageorgiou, V. Pappa, 2015, Clinical Cancer Research.

Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation.

D. Margaritis, I. Kotsianidis, G. Bourikas, 2008, Leukemia research.